You are here:

Meldex highlights takeover credentials

Created:
17 March 2008
Written by:
Richard Hemming

Speciality pharmaceuticals company Meldex reinforced its credentials as a takeover candidate by issuing an impressive update to shareholders outlining progress across its broad product suite. The company sells over 30 products, as well as ones in development.

Advertising

The company is particularly excited about its "FastWrap" version of the headache-relieving compound, ibuprofen, which it says has a faster action than any product so far marketed.

SHARE TIP UPDATE:

Buy

The share price has been volatile, but takeover discussions are continuing and this announcement reinforces its saleability. At 70p, it is above our initial buy rating (60p on 31 Dec 2007) and remains a buy.

For more tip updates, see www.investorschronicle.co.uk/Tips

  • Back to top

Win £1,000 or a golf weekend

Enter IC's Fantasy Portfolio competition for the chance of winning £1,000 or a luxury golf weekend, courtesy of ETX Capital and Celtic Manor.

Enter here for your chance to win

Advertorial Feature

Take control of your investing with CFDs

Have you ever watched a move in the markets that you saw coming, but you weren't able to exploit?

by Dominic Picarda

Advertorial Feature

Spread your risks with spread trading

With so many big moves in the world's financial markets, there have seldom been more opportunities around for spread traders. Isn't it time you joined them?

by Dominic Picarda